GEN Exclusives

More »

GEN News Highlights

More »
Apr 6, 2009

Mitsubishi Tanabe Signs On Affectis for Discovery Work for Antidepressants

  • Mitsubishi Tanabe Pharma (MTPC) will use Affectis Pharmaceuticals’ behavioral pharmacology expertise and technology in its drug discovery efforts. Affectis will receive research fees and is eligible to developmental milestones. 
     
    MTPC’s ongoing drug discovery program is reportedly based on a novel depression target that Affectis helped validate in a previous collaboration. The deal, which was inked in February 2005, covered the use of Affectis’ Behavioural Interference™ platform.

    Under the new agreement, MTPC will continue to utilize this technology and Affectis’ expertise. Affectis has two antidepressant discovery programs and one Phase II candidate for depression.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?